The NIAID has awarded the University of Alabama at Birmingham Department of Pediatrics a $10. million contract to conduct a multicenter, multinational natural history study of acute flaccid myelitis (AFM) in pediatric patients.
Researchers at the Icahn School of Medicine at Mount Sinai have developed a novel vaccine consisting of DNA and recombinant proteins⸺proteins composed of a portion of an HIV protein and another unrelated protein.
This study, co-led by Samantha Meltzer-Brody, MD, MPH, director of the UNC Perinatal Psychiatry Program, and Daisy Singla, PhD, assistant professor of psychiatry at University of Toronto and clinician scientist at Sinai Health System, will investigate how to make talk therapy treatment – specifically behavioral activation – more accessible to all women.
A highly competitive $4.5 million grant from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) will support Keck School of Medicine of USC efforts to recruit patients from underrepresented populations into cardiac surgery clinical trials.
SimPHARM is a clinical therapeutic simulation tool that creates a realistic clinical experience in which one minute of virtual time equals one minute of real time. Ideal for flipped classroom learning environments, the platform's cognitive game engine empowers students to develop their clinical decision-making skills at their own pace while under the supervision of faculty. It is built on mathematical models of the physiology of body systems that simulates real life reactions to diseases and drugs. This allows the student to sense and feel the consequences of their decisions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bio-Rad’s IH-500, an automated random access system for blood typing and screening.
A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine. The drug, rimegepant, is awaiting U.S. Food and Drug Administration approval and may offer advantages over currently available migraine medications. The study was led by researchers at Albert Einstein College of Medicine and Montefiore Health System.
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients. Over 850 million people suffer from kidney diseases worldwide, a number which signifies epidemic proportions, yet these patients are still ignored by investigators and initiators of clinical trials in all medical fields – and are thus excluded from clinical trials. ASN, ERA-EDTA and ISN, collaboratively aim to bring about a paradigm change in medical research and have launched an information campaign to that end.
Patients with sickle cell disease experience severe organ damage leading to early death. An international clinical trial funded by the NIH will test whether red cell exchange, which replaces sicked red blood cells with normal ones could prevent or reverse organ damage and prolong life.
In the first clinical trial of its kind, researchers hope to discover whether following the ketogenic diet will help patients with acute spinal cord injuries regain sensory and motor functions faster than those who do not follow the diet.
The males of one species of butterfly are more attracted to females that are active, not necessarily what they look like, according to a recent research conducted at Augustana University.The paper, “Behaviour before beauty: Signal weighting during mate selection in the butterfly Papilio polytes,” found that males of the species noticed the activity levels of potential female mates, not their markings.
Suicide and attempt rates are greatly elevated among patients after discharge from psychiatric hospitalization – especially during the first year after discharge, concludes a research review in the July/August issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Irvine, Calif., July 8, 2019 — University of California, Irvine researchers have developed and tested on mice a therapeutic treatment that uses engineered stem cells to target and kill cancer bone metastases while preserving the bone. This new approach, reported in the journal EBioMedicine, equips engineered mesenchymal stem cells with targeting agents that drive them to bone metastatic sites, where they offload therapeutics.
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Intermountain Healthcare has earned top accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for ensuring the highest protections for participants in Intermountain clinical research studies.
Decisions to prescribe children drugs to treat chronic pain are not guided by sufficient, high quality evidence, according to an important new study published today (Wednesday 26 June 2019).
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that individuals reported more gastrointestinal bloating when they ate a diet high in salt.
Three abstracts focused on improving clinical trials processes have been selected for formal presentation at the Association of American Cancer Institutes’ Clinical Research Innovation annual meeting, July 9-11, in Chicago.
Hackensack Meridian Health Ocean Medical Center Foundation raised nearly $250,000 at the 29th Annual Golf Classic, which took place on June 17 at Manasquan River Golf Club in Brielle. This year’s event welcomed 120 golfers who competed in the tournament to raise money for programs and services at Hackensack Meridian Health Ocean Medical Center.
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients. The researchers sought to identify potential interventions – i.e., solutions – to improve the situation.
Multi-institution collaboration is the first in the western U.S. to perform completely laparoscopic repair of open spina bifida
University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
Issues like age or existing arthritis may preclude patients from participating in clinical studies for new therapies that could benefit them
BOSTON – (June 11, 2019) – Researchers from Joslin Diabetes Center, using a genome-wide association study, have identified a genetic factor linked to the development of diabetic peripheral neuropathy. This finding suggests a new target for preventive therapies. The research has been published online and will appear in the August print issue of Diabetes.
L’Institut et hôpital neurologiques de Montréal (le Neuro) dirigera un partenariat en science ouverte en vue de la mise au point de médicaments de précision indiqués dans la sclérose latérale amyotrophique (SLA) et la maladie de Parkinson (MP).
The Neuro (Montreal Neurological Institute and Hospital) will lead an open science partnership to develop precision drugs for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
When prescribed the anticoagulant drug warfarin, many patients are told to limit foods rich in vitamin K, such as green vegetables. The results of a new clinical trial call that advice into question and suggest patients on warfarin actually benefit from increasing their vitamin K intake—as long as they keep their intake levels consistent.
AMP has revised its official position for all consumer genomic testing. Based on a recent assessment of the current market landscape and privacy best practices, the latest position statement features an expanded list of conditions that must be met before AMP can support a clinically-meaningful test.
A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes. During more than five years of follow-up, cardiovascular events like heart attacks and strokes were reduced by 12% in people taking dulaglutide compared to people taking a placebo. This effect was seen in both men and women with or without previous cardiovascular disease.
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL).
Results of a phase 3 clinical trial by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that women with HER2-positive breast cancer had significantly better response rates, but more severe side effects, when they were treated with traditional neoadjuvant chemotherapy along with dual HER2-targeted blockade, compared to a more novel approach using HER2-targeted chemotherapy plus HER2-targeted blockade.
There are no approved treatment options for patients with advanced bladder cancer after standard chemotherapy and immune treatments, but the results of a phase II clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers demonstrates an effective treatment for this deadly disease.
Georgetown University Medical Center announces the launch of the only known therapeutic (disease modifying) clinical trial for Lewy body dementia, a neurological disorder that affects a million people in the United States for which there are no approved medications that modify the disease.
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center.
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers. This publication accompanies a presentation today that outlines the study results at the American Society for Clinical Oncology (ASCO). Researchers found that treatment with apalutamide significantly improved overall survival, with a 33% reduction in risk of death compared to standard-of-care therapy. Additionally, this study showed apalutamide significantly delayed disease progression and increased the amount of time until a patient has to receive chemotherapy.
Studies to be presented at the ASCO meeting are co-authored by research oncologists Eric Whitman, MD; Missak Haigentz, MD; and Angela Alistar, MD. Their ASCO studies include: two separate studies looking at TILS therapy and Keytruda for advanced melanoma; immunotherapy for metastatic head and neck cancer; treatment for recurrent Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma; and a combination of CPI-613 -- a new type of medication, pioneered by Dr. Alistar, known as an altered energy metabolism drug -- with 5-FU in treating metastatic colorectal cancer.
UNMC is the only institution in the central plains region participating in the research. Globally, 880 patients will be enrolled at 130 sites in 20 countries. Researchers will follow patients for up to five years.
Clinical Research Pathways, a non-profit that advocates for increasing diversity in clinical research and expanding access to experimental drugs, biologics and medical devices, has added a new member to its board of directors.
Findings from Rutgers Cancer Institute of New Jersey focused on immunotherapy will be featured at the 2019 American Society of Clinical Oncology Annual Meeting being held in Chicago tomorrow through Tuesday.
Cancer patients previously excluded and underrepresented in immunotherapy clinical trials, such as African Americans and patients with HIV or viral hepatitis, actually benefit at the same rate as patients tested in the clinical trials, according to a Georgetown-led study to be presented at the 2019 ASCO Annual Meeting in Chicago.
A survey conducted by Georgetown investigators found a significant knowledge and practice gap among community oncologists in the understanding and usage of genetic testing in determining patients' treatment plans and potential clinical trial outcomes.
Something as simple as a phone call could be a way to alert health care providers and caregivers that an elderly person suffering from dementia may be spiraling down to dangerous self-neglect, according to researchers at The University of Texas Health Science Center at Houston (UTHealth).
Fred Hutchinson Cancer Research Center’s latest findings in immunotherapy, prevention of cancer-linked viruses, health care disparities and more will be showcased at the annual meeting of the American Society of Clinical Oncology. The conference, “Caring for Every Patient, Learning from Every Patient,” will be held May 31-June 4 in Chicago. See highlights below.
Today, the Journal of the American College of Radiology (JACR®) published a report detailing real-world artificial intelligence (AI) challenges and summarizing the priorities for translational research in AI for medical imaging to help accelerate the safe and effective use of AI in clinical practice.
The Cancer Research Institute announced today a series of public education and awareness offerings during its seventh annual Cancer Immunotherapy Month™ in June.
A new method of assessing the actions of medicines by matching them to their unique protein receptors has the potential to greatly accelerate drug development and diminish the number of drug trials that fail during clinical trials.
Case Comprehensive Cancer Center has been selected, once again, as a Lead Academic Participating Site by the National Cancer Institute. The renewal comes with a six-year, $8.9 million grant that will enable the center to provide patients with additional access to clinical trials through the National Clinical Trials Network. In this renewal, NCI is committed to improving the resources provided for each patient to cover research costs at levels linked to the complexity of the clinical trial.
As many as 90 percent of individuals who have a parent with Huntington’s disease (HD) choose not to take a gene test that reveals if they will also develop the fatal disorder — and a new study details the reasons why. Understanding the “why” matters as new clinical trials testing therapies for people who haven’t yet developed symptoms of Huntington disease requires participants to be tested for the HD gene to be included in the trials.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right